12.50Open12.50Pre Close0 Volume2 Open Interest22.50Strike Price0.00Turnover545.92%IV-118.34%PremiumDec 20, 2024Expiry Date17.92Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6999Delta0.0577Gamma0.25Leverage Ratio-0.0469Theta-0.0087Rho-0.17Eff Leverage0.0039Vega
Nevro Stock Discussion
6 mins ago
Nevro's Hfx Iq™ Spinal Cord Stimulation With AI Technology Receives Ce Mark Certification in Europe, Increasing Product Expansion Globally
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
Nevro Corp. (NYSE: NVRO) has announced the FDA approval and market release of HFX iQ™ with HFX AdaptivAI™, an AI-driven spinal cord stimulation (SCS) system for chronic pain management. This technology leverages insights from over 100,000 patients and more than 100 million data points to provide personalized, responsive pain relief in real time.
Key features of HFX Adaptiv...
News:
• $PyroGenesis Canada (PYR.US)$ +5.9% (announces that the negotiation for the land-based system to destroy PFAS contract has been suspended and discontinued)
• $Immatics (IMTX.US)$ +3.1% (announces a clinical data update for the IMA203)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +1.6% (rising with softness in futures)
• $Nevro (NVRO.US)$ +1.4% (comments on $UnitedHealth (UNH.US)$ medical coverage policy u...
No comment yet